Compare AstraZeneca plc (AZN) vs Eaton Corporation plc (ETN) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

Eaton Corporation (ETN) trades at $402.85, down 1.09% on the day, with a bearish technical signal from moving averages. The stock exhibits strong fundamentals, including a 13.99% net income margin and consistent quarterly earnings beats, most recently in Q1 2026. Recent news highlights growth in data center and aerospace markets, supported by strategic acquisitions and a $2.1 billion R&D investment in 2025.

The outlook remains positive, driven by robust analyst sentiment with a $449.50 consensus price target and no sell ratings. Key opportunities include exposure to high-growth infrastructure and AI-related power demand. Risks involve elevated valuation multiples, such as a P/E of 40.66, and potential execution challenges from recent investments, with Q2 2026 earnings on July 31, 2026, serving as a near-term catalyst.